One of the most important things to look for when establishing a new pharmaceutical or biotech company is scientific talent in the region.
Terapinn has compiled a list of the top innovations that will be presented at BioPharma Mexico 2013. Each of these projects were selected because of their originality and relevance to the pharmaceutical and biotech industries. But most importantly, these projects show that there is scientific talent in Mexico, which makes it ideal to conduct clinical development of any type.
This ranking was built based on the novelty of each project and its relevance to the pharmaceutical and health industries. The selection criteria are based on the following:
• Originality of research
• Relevance to industry
• Technology
• Clinical stage of project
• Projected impact
The innovators are listed in alphabetical order by project and are not ranked within the 9.
## Production of Vaccines Fused to Genetically Encoded Nanocrystals
Innovator Scientist: Luis Vaca, CaramelTech
Innovation:
Baculovirus expression system for insect cells (BEVS) is a novel procedure used to make stable proteins that can be used in vaccines. It takes advantage of the polyhedrin production system in insect cultures to manufacture effective recombinant proteins. This process requires the fusion of a recombinant sequence with a polyhedrin sequence which is then inserted into a BEVS factor, resulting in production of high amounts of encapsulated proteins that are resistant to heat and dehydration.
## MedicalHub: Health maps of Mexico
Innovator Scientist: Ivan Pech, CaramelTech
Innovation:
Medical Hub is a big data project that makes health statistics available to the private sector in Mexico and Latin America. One of its components is Medical Metrics, which creates health maps with health graphics and indicators for each city, state, and country. Medical Manik complements it by allowing doctors to control their patients records on the go. Medical Hub will benefit pharma by facilitating the application of big data to the
developing and monitoring of novel therapies and the generation of new health initiatives.
Wednesday, October 9, 2013
Monday, October 7, 2013
Purpose of Bioavailability Studies | Book Excerpt
Bioavailability means the rate and extent to which the active ingredient or
active moiety is absorbed from a drug product and becomes available at the site
of action. For drug products that are not intended to be absorbed into the
bloodstream, bioavailability may be assessed by measurements intended to reflect
the rate and extent to which the active ingredient or active moiety becomes
available at the site of action.
Bioavailability studies are performed for both approved
active drug ingredients and therapeutic moieties not yet approved for marketing
by the FDA. New formulations of active drug ingredients must be approved by the
FDA before marketing. In approving a drug product for marketing, the FDA ensures
that the drug product is safe and effective for its labeled indications for use.
Moreover, the drug product must meet all applicable standards of identity,
strength, quality, and purity. To ensure that these standards are met, the FDA
requires bioavailability/pharmacokinetic studies and, where necessary,
bioequivalence studies for all drug products (FDA Guidance for Industry,
2003). Bioavailability may be considered as one aspect of drug product quality
that links in-vivo performance of the drug product used in clinical
trials to studies demonstrating evidence of safety and efficacy.
India is flooding the world with tainted drugs - and getting away with it | Foreign Policy
This article was first published on Foreign Policy News on 4th October. This is just a magnet part of the article, if you want to read the full article, you must have to visit their website here.
(By Roger Bate) Each time we take medicine, we assume that the manufacturer did its best to produce a quality product. Evidence is mounting, however, that some pharmaceutical manufacturers in countries like India cut corners and send low-quality products to major, developed markets. Worse still, they may have separate production lines for drugs they sell in developing markets like Africa, where poor quality is more likely to go unnoticed.
In mid-2013, India's largest drugmaker, Ranbaxy, pleaded guilty in a U.S. court to several criminal offenses relating to the fraudulent manufacture and sale of adulterated drugs. (The United States is the biggest importer of generic Indian drugs.) Among other revelations, Ranbaxy's executives acknowledged that "more than 200 products in more than 40 countries" are affected by "elements of data that were fabricated to support [Ranbaxy's] business needs." In other words, Ranbaxy made up facts and figures to demonstrate product safety for myriad drugs, including critical HIV medicines paid for by U.S. tax dollars and destined for the poor in Africa. As a consequence, the company was fined $500 million.
The Indian government, protective of its country's $20 billion pharmaceutical industry, quickly responded by claiming that Indian drugs are in fact safe. But in September, the U.S. Food and Drug Administration banned imports of drugs from another Ranbaxy plant that had not been implicated in the recent settlement.
BAD MEDICINE
(By Roger Bate) Each time we take medicine, we assume that the manufacturer did its best to produce a quality product. Evidence is mounting, however, that some pharmaceutical manufacturers in countries like India cut corners and send low-quality products to major, developed markets. Worse still, they may have separate production lines for drugs they sell in developing markets like Africa, where poor quality is more likely to go unnoticed.
In mid-2013, India's largest drugmaker, Ranbaxy, pleaded guilty in a U.S. court to several criminal offenses relating to the fraudulent manufacture and sale of adulterated drugs. (The United States is the biggest importer of generic Indian drugs.) Among other revelations, Ranbaxy's executives acknowledged that "more than 200 products in more than 40 countries" are affected by "elements of data that were fabricated to support [Ranbaxy's] business needs." In other words, Ranbaxy made up facts and figures to demonstrate product safety for myriad drugs, including critical HIV medicines paid for by U.S. tax dollars and destined for the poor in Africa. As a consequence, the company was fined $500 million.
The Indian government, protective of its country's $20 billion pharmaceutical industry, quickly responded by claiming that Indian drugs are in fact safe. But in September, the U.S. Food and Drug Administration banned imports of drugs from another Ranbaxy plant that had not been implicated in the recent settlement.
Friday, October 4, 2013
Pharmaceutical Industry Article: In vitro Dissolution Profile acts as a Pre-assessment Tool for Bioequivalence Study of Generic Pharmaceutical Oral Solid Products.
About Author: This article was Exclusively Written for Pharma Mirror Readers by Mohammad Dulal, Industrial Pharmacist licensed in MOH/Dubai, Senior Scientist, Product Development Lab, Julphar Gulf Pharmaceutical Ltd, Ras Al Khaimah, United Arab Emirates.
1.0 Introduction
Generic pharmaceutical products are clone of innovator products in the term of actives, strengths, dosage forms, dosage regimens and administrations. Actual fact is that innovator companies are very less in numbers in the world due to requirement of huge investment. Innovator companies are also not in good numbers enough to serve their medicines to all the worldwide patients. Reasonably, generic companies are established to serve their local patients with medicines at a manageable price. Generic companies cannot
Pharmaceutical Industry Poem: Quality and Productivity | Pharma Mirror Magazine
Where there
is safety there is Quality.
Meeting
indication is Quality.
Fitness for
use is Quality.
Rational
interaction is Quality.
Get the job
right the first time is Quality.
Less adverse
effect is Quality.
Customer’s satisfaction is Quality.
Defect free
is Quality.
In-process
control is Quality.
Statistical
control is Quality.
Control
within range/ limit is Quality.
Execution of
jobs as per SOPs is Quality.
Validated
process is Quality.
Validated
environment is Quality.
Vigilance
supervision is Quality.
Continuous
improvement is Quality.
Stepwise
work is Quality.
Subscribe to:
Posts (Atom)